{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:40:47Z","timestamp":1788489647985,"version":"build-2803163510"},"reference-count":67,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mantle cell lymphoma (MCL) is an incurable B-cell malignancy that comprises up to 6% of non-Hodgkin lymphomas diagnosed annually and is associated with a poor prognosis. The average overall survival of patients with MCL is 5 years, and for most patients who progress on targeted agents, survival remains at a dismal 3 to 8\u00a0months. There is a major unmet need to identify new therapeutic approaches that are well tolerated to improve treatment outcomes and quality of life. The protein arginine methyltransferase 5 (PRMT5) enzyme is overexpressed in MCL and promotes growth and survival. Inhibition of PRMT5 drives antitumor activity in MCL cell lines and preclinical murine models. PRMT5 inhibition reduced the activity of prosurvival AKT signaling, which led to the nuclear translocation of FOXO1 and modulation of its transcriptional activity. Chromatin immunoprecipitation and sequencing identified multiple proapoptotic BCL-2 family members as FOXO1-bound genomic loci. We identified BAX as a direct transcriptional target of FOXO1 and demonstrated its critical role in the synergy observed between the selective PRMT5 inhibitor, PRT382, and the BCL-2 inhibitor, venetoclax. Single-agent and combination treatments were performed in 9 MCL lines. Loewe synergy scores showed significant levels of synergy in most MCL lines tested. Preclinical, in\u00a0vivo evaluation of this strategy in multiple MCL models showed therapeutic synergy with combination venetoclax\/PRT382 treatment with an increased survival advantage in 2 patient-derived xenograft models (P \u2264 .0001, P \u2264 .0001). Our results provide mechanistic rationale for the combination of PRMT5 inhibition and venetoclax to treat patients with MCL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009906","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T16:43:27Z","timestamp":1686933807000},"page":"6211-6224","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6692-8678","authenticated-orcid":false,"given":"Fiona","family":"Brown-Burke","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-9374","authenticated-orcid":false,"given":"Inah","family":"Hwang","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Sloan","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"},{"name":"3Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hinterschied","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoBeth","family":"Helmig-Mason","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Long","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"},{"name":"3Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1521","authenticated-orcid":false,"given":"Wing Keung","family":"Chan","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Prouty","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hyun","family":"Chung","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Prelude Therapeutics, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-9566","authenticated-orcid":false,"given":"Satishkumar","family":"Singh","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Youssef","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Bhagwat","sequence":"additional","affiliation":[{"name":"4Prelude Therapeutics, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengming","family":"Chen","sequence":"additional","affiliation":[{"name":"5Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Chen-Kiang","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Di Liberto","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Elemento","sequence":"additional","affiliation":[{"name":"6Department of Physiology & Biophysics, Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-5427","authenticated-orcid":false,"given":"Lalit","family":"Sehgal","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Vaddi","sequence":"additional","affiliation":[{"name":"4Prelude Therapeutics, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Scherle","sequence":"additional","affiliation":[{"name":"4Prelude Therapeutics, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Lapalombella","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Paik","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-4853","authenticated-orcid":false,"given":"Robert A.","family":"Baiocchi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"issue":"11","key":"2023102417105901100_bib1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023102417105901100_bib2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"issue":"15","key":"2023102417105901100_bib3","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1080\/14656566.2019.1642871","article-title":"Clinical management of mantle cell lymphoma in the elderly","volume":"20","author":"Smolewski","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"2023102417105901100_bib4","author":"Freedman","year":"2019"},{"issue":"6","key":"2023102417105901100_bib5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"key":"2023102417105901100_bib6","author":"US Food and Drug Administration","year":"2020"},{"issue":"6","key":"2023102417105901100_bib7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"2023102417105901100_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.critrevonc.2011.05.001","article-title":"Mantle cell lymphoma","volume":"82","author":"Cortelazzo","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"35","key":"2023102417105901100_bib9","doi-asserted-by":"crossref","first-page":"32971","DOI":"10.1074\/jbc.M105412200","article-title":"PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins","volume":"276","author":"Branscombe","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"2023102417105901100_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41467-018-07884-6","article-title":"PRMT5 is essential for B cell development and germinal center dynamics","volume":"10","author":"Litzler","year":"2019","journal-title":"Nat Commun"},{"issue":"16","key":"2023102417105901100_bib11","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2014-12-619783","article-title":"Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation","volume":"125","author":"Alinari","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2023102417105901100_bib12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/leu.2015.308","article-title":"The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation","volume":"30","author":"Tarighat","year":"2016","journal-title":"Leukemia"},{"issue":"49","key":"2023102417105901100_bib13","doi-asserted-by":"crossref","first-page":"35534","DOI":"10.1074\/jbc.M113.510669","article-title":"Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing","volume":"288","author":"Chung","year":"2013","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"2023102417105901100_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A\u00a0selective inhibitor of PRMT5 with in\u00a0vivo and in\u00a0vitro potency in MCL models","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat Chem Biol"},{"issue":"10","key":"2023102417105901100_bib15","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1172\/JCI85239","article-title":"Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia","volume":"126","author":"Jin","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"2023102417105901100_bib16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2159-8290.CD-14-0625","article-title":"PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers","volume":"5","author":"Li","year":"2015","journal-title":"Cancer Discov"},{"issue":"3","key":"2023102417105901100_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.gendis.2019.06.002","article-title":"PRMT5 in gene regulation and hematologic malignancies","volume":"6","author":"Zhu","year":"2019","journal-title":"Genes Dis"},{"issue":"15","key":"2023102417105901100_bib18","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1038\/sj.emboj.7601794","article-title":"Low levels of miR-92b\/96 induce PRMT5 translation and H3R8\/H4R3 methylation in mantle cell lymphoma","volume":"26","author":"Pal","year":"2007","journal-title":"EMBO J"},{"issue":"12","key":"2023102417105901100_bib19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/ncb1802","article-title":"Arginine methylation regulates the p53 response","volume":"10","author":"Jansson","year":"2008","journal-title":"Nat Cell Biol"},{"issue":"15","key":"2023102417105901100_bib20","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1093\/nar\/gkp516","article-title":"PRMT5 is required for cell-cycle progression and p53 tumor suppressor function","volume":"37","author":"Scoumanne","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"33","key":"2023102417105901100_bib21","doi-asserted-by":"crossref","first-page":"13516","DOI":"10.1073\/pnas.1311784110","article-title":"PRMT5 dimethylates R30 of the p65 subunit to activate NF-\u03baB","volume":"110","author":"Wei","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"2023102417105901100_bib22","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2018-02-831438","article-title":"PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival","volume":"132","author":"Lu","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2023102417105901100_bib23","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/emboj.2012.17","article-title":"Arginine methylation controls growth regulation by E2F-1","volume":"31","author":"Cho","year":"2012","journal-title":"EMBO J"},{"issue":"1","key":"2023102417105901100_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molcel.2013.08.039","article-title":"Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1","volume":"52","author":"Zheng","year":"2013","journal-title":"Mol Cell"},{"issue":"11","key":"2023102417105901100_bib25","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1158\/2159-8290.CD-20-0026","article-title":"PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2","volume":"10","author":"Pastore","year":"2020","journal-title":"Cancer Discov"},{"issue":"2","key":"2023102417105901100_bib26","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/jcmm.14036","article-title":"Targeting PRMT5\/Akt signalling axis prevents human lung cancer cell growth","volume":"23","author":"Zhang","year":"2019","journal-title":"J\u00a0Cell Mol Med"},{"issue":"6","key":"2023102417105901100_bib27","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1158\/0008-5472.CAN-13-0884","article-title":"Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma","volume":"74","author":"Yan","year":"2014","journal-title":"Cancer Res"},{"issue":"12","key":"2023102417105901100_bib28","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1016\/j.celrep.2017.11.096","article-title":"PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression","volume":"21","author":"Chiang","year":"2017","journal-title":"Cell Rep"},{"issue":"2","key":"2023102417105901100_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/onc.2016.199","article-title":"PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells","volume":"36","author":"Banasavadi-Siddegowda","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"2023102417105901100_bib30","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1038\/s41598-018-28002-y","article-title":"Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing","volume":"8","author":"Gerhart","year":"2018","journal-title":"Sci Rep"},{"issue":"23","key":"2023102417105901100_bib31","doi-asserted-by":"crossref","first-page":"23892","DOI":"10.1074\/jbc.M401853200","article-title":"Small molecule regulators of protein arginine methyltransferases","volume":"279","author":"Cheng","year":"2004","journal-title":"J\u00a0Biol Chem"},{"issue":"10","key":"2023102417105901100_bib32","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1021\/acsmedchemlett.1c00512","article-title":"Novel PRMT5 inhibitors for treating cancer","volume":"12","author":"Sabnis","year":"2021","journal-title":"ACS Med Chem Lett"},{"issue":"11","key":"2023102417105901100_bib33","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.bmcl.2019.03.042","article-title":"Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors","volume":"29","author":"Lin","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"19","key":"2023102417105901100_bib34","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1074\/jbc.RA119.007640","article-title":"Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT\/\u03b2-catenin and AKT\/GSK3\u03b2 proliferative signaling","volume":"294","author":"Chung","year":"2019","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"2023102417105901100_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"8","key":"2023102417105901100_bib36","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4161\/cbt.8.8.7927","article-title":"Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells","volume":"8","author":"Golding","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"24","key":"2023102417105901100_bib37","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1101\/gad.854900","article-title":"Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation","volume":"14","author":"Alt","year":"2000","journal-title":"Genes Dev"},{"issue":"24","key":"2023102417105901100_bib38","doi-asserted-by":"crossref","first-page":"21843","DOI":"10.1074\/jbc.M109745200","article-title":"Akt enhances Mdm2-mediated ubiquitination and degradation of p53","volume":"277","author":"Ogawara","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"2023102417105901100_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fcell.2019.00070","article-title":"Akt-ing up just about everywhere: compartment-specific akt activation and function in receptor tyrosine kinase signaling","volume":"7","author":"Sugiyama","year":"2019","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"2023102417105901100_bib40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4161\/cbt.12.4.15954","article-title":"FoxO family members in cancer","volume":"12","author":"Zhang","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"2023102417105901100_bib41","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.semcancer.2017.07.007","article-title":"Role of forkhead box class O proteins in cancer progression and metastasis","volume":"50","author":"Kim","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"24","key":"2023102417105901100_bib42","doi-asserted-by":"crossref","first-page":"17179","DOI":"10.1074\/jbc.274.24.17179","article-title":"Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B","volume":"274","author":"Rena","year":"1999","journal-title":"J\u00a0Biol Chem"},{"issue":"12","key":"2023102417105901100_bib43","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/ni.1667","article-title":"Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation","volume":"9","author":"Dengler","year":"2008","journal-title":"Nat Immunol"},{"issue":"3","key":"2023102417105901100_bib44","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2003-09-3071","article-title":"Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors","volume":"104","author":"Yusuf","year":"2004","journal-title":"Blood"},{"issue":"6779","key":"2023102417105901100_bib45","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/35008115","article-title":"AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1","volume":"404","author":"Medema","year":"2000","journal-title":"Nature"},{"issue":"1","key":"2023102417105901100_bib46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1535-6108(02)00086-7","article-title":"A\u00a0novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR","volume":"2","author":"Ramaswamy","year":"2002","journal-title":"Cancer Cell"},{"issue":"7","key":"2023102417105901100_bib47","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ncb2069","article-title":"Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity","volume":"12","author":"Zhao","year":"2010","journal-title":"Nat Cell Biol"},{"issue":"4","key":"2023102417105901100_bib48","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/15548627.2015.1023981","article-title":"Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways","volume":"11","author":"Zhang","year":"2015","journal-title":"Autophagy"},{"issue":"7","key":"2023102417105901100_bib49","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1245\/s10434-009-0481-x","article-title":"Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma","volume":"16","author":"Zhang","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"2023102417105901100_bib50","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0145-2126(03)00102-4","article-title":"Constitutive phosphorylation of FKHR transcription factor as a prognostic variable in acute myeloid leukemia","volume":"27","author":"Cheong","year":"2003","journal-title":"Leuk Res"},{"issue":"1","key":"2023102417105901100_bib51","doi-asserted-by":"crossref","first-page":"17370","DOI":"10.1038\/s41598-018-35459-4","article-title":"FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas","volume":"8","author":"Grupp","year":"2018","journal-title":"Sci Rep"},{"issue":"12","key":"2023102417105901100_bib52","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1038\/s41375-019-0489-6","article-title":"PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K\/AKT in lymphoma cells","volume":"33","author":"Zhu","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2023102417105901100_bib53","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1038\/s41467-021-23833-2","article-title":"PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis","volume":"12","author":"Yin","year":"2021","journal-title":"Nat Commun"},{"issue":"18","key":"2023102417105901100_bib54","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"9","key":"2023102417105901100_bib55","doi-asserted-by":"crossref","first-page":"e135826","DOI":"10.1172\/jci.insight.135826","article-title":"CIC is a critical regulator of neuronal differentiation","volume":"5","author":"Hwang","year":"2020","journal-title":"JCI Insight"},{"issue":"10","key":"2023102417105901100_bib56","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.2022019419","article-title":"PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma","volume":"142","author":"Sloan","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2023102417105901100_bib57","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccell.2016.06.008","article-title":"The public repository of xenografts enables discovery and randomized phase II-like trials in mice","volume":"30","author":"Townsend","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"2023102417105901100_bib58","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41467-022-35778-1","article-title":"Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation","volume":"14","author":"Hing","year":"2023","journal-title":"Nat Commun"},{"issue":"11","key":"2023102417105901100_bib59","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.bbamcr.2010.11.025","article-title":"Structural basis for DNA recognition by FOXO proteins","volume":"1813","author":"Obsil","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"2023102417105901100_bib60","article-title":"Venetoclax (Venclexta) tablets","year":"2016","journal-title":"US Food and Drug Administration"},{"issue":"6","key":"2023102417105901100_bib61","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"2023102417105901100_bib62","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"issue":"16","key":"2023102417105901100_bib63","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1002\/cam4.2565","article-title":"Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience","volume":"8","author":"Jeon","year":"2019","journal-title":"Cancer Med"},{"issue":"4","key":"2023102417105901100_bib64","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"24","key":"2023102417105901100_bib65","doi-asserted-by":"crossref","first-page":"e160767","DOI":"10.1172\/JCI160767","article-title":"A\u00a0FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas","volume":"132","author":"Jang","year":"2022","journal-title":"J\u00a0Clin Invest"},{"key":"2023102417105901100_bib66","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1038\/ncomms9419","article-title":"Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis","volume":"6","author":"Hu","year":"2015","journal-title":"Nat Commun"},{"key":"2023102417105901100_bib67","unstructured":"NCBI\n          . Gene: 10419 PRMT5 protein arginine methyltransferase 5. 2021. Accessed 5 July 2023. https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=10419."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6211\/2085174\/blooda_adv-2023-009906-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6211\/2085174\/blooda_adv-2023-009906-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T17:22:18Z","timestamp":1698168138000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/20\/6211\/496393\/PRMT5-inhibition-drives-therapeutic-vulnerability"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":67,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009906","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}